Heron Therapeutics (HRTX) Total Non-Current Liabilities (2022 - 2026)

Heron Therapeutics (HRTX) has 5 years of Total Non-Current Liabilities data on file, last reported at $232.2 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 11.91% year-over-year to $232.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $232.2 million (down 11.91% YoY) and the FY2025 annual result came in at $236.7 million, down 11.06% from the prior year.
• Total Non-Current Liabilities slipped to $232.2 million in Q1 2026, from $236.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $266.2 million in Q4 2024 to a low of $229.4 million in Q3 2025.
• A 5-year average of $249.5 million and a median of $251.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities increased 8.34% — and 2025, when it fell 11.96%.
• Tracing HRTX's Total Non-Current Liabilities over 5 years: stood at $237.1 million in 2022, then rose by 8.05% to $256.2 million in 2023, then advanced by 3.88% to $266.2 million in 2024, then retreated by 11.06% to $236.7 million in 2025, then decreased by 1.94% to $232.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $232.2 million (Q1 2026), $236.7 million (Q4 2025), and $229.4 million (Q3 2025), per Business Quant data.